Literature DB >> 31897724

Orodispersible Carbamazepine/Hydroxypropyl-β-Cyclodextrin Tablets Obtained by Direct Compression with Five-in-One Co-processed Excipients.

Jaime Conceição1, Oluwatomide Adeoye2, Helena Cabral-Marques2, Angel Concheiro3, Carmen Alvarez-Lorenzo3, José Manuel Sousa Lobo4.   

Abstract

The development of orodispersible tablets (ODTs) for poorly soluble and poorly flowable drugs via direct compression is still a challenge. This work aimed to develop ODTs of poorly soluble drugs by combining cyclodextrins that form inclusion complexes to improve wetting and release properties, and directly compressible co-processed excipients able to promote rapid disintegration and solve the poor flowability typical of inclusion complexes. Carbamazepine (CBZ) and hydroxypropyl-β-cyclodextrin (HPβCD) were used, respectively, as a model of a poorly soluble drug with poor flowability and as a solubilizing agent. Specifically, CBZ-an antiepileptic and anticonvulsant drug-may benefit from the studied formulation approach, since some patients have swallowing difficulties or fear of choking and are non-cooperative. Prosolv® ODT G2 and F-Melt® type C were the studied five-in-one co-processed excipients. The complex was prepared by kneading. Flow properties of all materials and main properties of the tablets were characterized. The obtained results showed that ODTs containing CBZ/HPβCD complex can be prepared by direct compression through the addition of co-processed excipients. The simultaneous use of co-processing and cyclodextrin technologies rendered ODTs with an in vitro disintegration time in accordance with the European Pharmacopoeia requirement and with a fast and complete drug dissolution. In conclusion, the combination of five-in-one co-processed excipients and hydrophilic cyclodextrins may help addressing the ODT formulation of poorly soluble drugs with poor flowability, by direct compression and with desired release properties.

Entities:  

Keywords:  F-Melt® type C; Prosolv® ODT G2; carbamazepine/hydroxypropyl-β-cyclodextrin complexes; direct compression; orally disintegrating tablets

Mesh:

Substances:

Year:  2020        PMID: 31897724     DOI: 10.1208/s12249-019-1579-5

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  3 in total

Review 1.  Orally Dispersible Dosage Forms for Paediatric Use: Current Knowledge and Development of Nanostructure-Based Formulations.

Authors:  Andreea Cornilă; Sonia Iurian; Ioan Tomuță; Alina Porfire
Journal:  Pharmaceutics       Date:  2022-08-03       Impact factor: 6.525

2.  Formulation of Chewable Tablets Containing Carbamazepine-β-cyclodextrin Inclusion Complex and F-Melt Disintegration Excipient. The Mathematical Modeling of the Release Kinetics of Carbamazepine.

Authors:  Adina Magdalena Musuc; Valentina Anuta; Irina Atkinson; Iulian Sarbu; Vlad Tudor Popa; Cornel Munteanu; Constantin Mircioiu; Emma Adriana Ozon; George Mihai Nitulescu; Mirela Adriana Mitu
Journal:  Pharmaceutics       Date:  2021-06-21       Impact factor: 6.321

3.  Formulation and Evaluation of Baclofen-Meloxicam Orally Disintegrating Tablets (ODTs) Using Co-Processed Excipients and Improvement of ODTs Performance Using Six Sigma Method.

Authors:  Rehab Abdelmonem; Menna M Abdellatif; Inas Essam Ibrahim Al-Samadi; Mohamed A El-Nabarawi
Journal:  Drug Des Devel Ther       Date:  2021-10-16       Impact factor: 4.162

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.